

cardiabioplastics.com info@cardiabioplastics.com

ASX CODE: CNN

TO: COMPANY ANNOUNCEMENTS OFFICE

ASX LIMITED

DATE: 3 December 2014

CLEANSING NOTICE-SHARE PLACEMENT & APPENDIX 3B

The Company provides the following information in accordance with sections 708A (5) (e) and (6) of the Corporations Act 2001 (Cwlth) ("the Act") in relation to share placement completed today.

- a) the Placement was made without disclosure to investors under Part 6D.2 of the Act;
- b) this Notice is given under section 708A(5)(e) of the Act;
- c) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act;
- d) As at the date of this Notice, there is no excluded information as defined under sections 708A(7) and (8) of the Act.

An Appendix 3B applying for quotation of the new securities is attached.

Richard Tegoni Chairman

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/09/01, \ 11/o3/02, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12 \ \ o1/o1/o3, \ o1$

entity	
Bioplastics Limited	
755237	
e entity) give ASX the following i	nformation.
I - All issues t complete the relevant sections (attach s	heets if there is not enough space).
*Class of *securities issued or to be issued	Fully Paid Ordinary Shares
Number of *securities issued or to be issued (if known) or maximum number which may be issued	50,000,000 fully paid Ordinary Shares
Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares ranking equally with ordinary shares from date of allotment.
	Bioplastics Limited 755237 e entity) give ASX the following i - All issues t complete the relevant sections (attach sections) + Class of + securities issued or to be issued Number of + securities issued or to be issued Number which may be issued Principal terms of the + securities (eg, if options, exercise price and expiry date; if partly paid + securities, the amount outstanding and due dates for payment; if + convertible securities, the conversion price

⁺ See chapter 19 for defined terms.

4

Do the +securities rank equally in all respects from the date of with ordinary shares from date of allotment. allotment with an existing +class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.002 (0.2 cents) per Share 5 Total amount raised - \$100,000 Securities issued pursuant to the Share placement 6 Purpose of the issue (If issued as consideration for the announced today (3/12/2014) acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 6b 28/11/2014 resolution under rule 7.1A was passed 50,000,000 6c Number of *securities issued without security holder approval under rule 7.1

Fully paid Ordinary Shares will equally

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	As per Annexure 1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	4 December 2014	
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	Number 3,764,432,502	+Class Fully Paid Ordinary Shares
		221,278,642	Listed Options (Expiry 30/6/2015 , Exercise price 1.5 cents)

⁺ See chapter 19 for defined terms.

	_		
		Number	+Class
9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	339,444,317	Options (Expiry 31/12/2014 ,Exercise Price 0.6 cents (\$0.006)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Bonus issue or pro	rata issue	
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	⁺ Class of ⁺ securities to which the offer relates	N/A	
15	⁺ Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A	
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	N/A	
20	Names of any underwriters	N/A	

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of securities (*tick one*)
- (a) Securities described in Part 1
- (b) \square All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37

A copy of any trust deed for the additional +securities

Appendix 3B Page 6 01/08/2012

⁺ See chapter 19 for defined terms.

ntitie	s that have ticked box 34(b)		
38	Number of securities for which ⁺ quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust,	N/A	
	 distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 38)	N/A	Class

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.

⁺ See chapter 19 for defined terms.

- There is no reason why those +securities should not be granted +quotation.
- An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date: 3/12/2014
	(Director/Company secretary)	

Company Secretary

Rekha Bhambhani

Print name:

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for $^+$ eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	2,696,092,168	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	900,007,001	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	118,333,333	
Number of partly paid ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-	
"A"	3,714,432,502	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	557,164,875
Step 3: Calculate "C", the amount of parties already been used	lacement capacity under rule 7.1 that
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	50,000,000
• Under an exception in rule 7.2	
• Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	50,000,000
Step 4: Subtract "C" from ["A" x "B"] capacity under rule 7.1	to calculate remaining placement
"A" x 0.15	557,164,875
Note: number must be same as shown in Step 2	
Subtract "C"	50,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	507,164,875
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	3,714,432,502	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	371,443,250	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	lacement capacity under rule 7.1A that	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	371,443,250	
Subtract "E" Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	371,443,250 Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.